154 related articles for article (PubMed ID: 31047306)
1. Ocular Metastasis of BRAF+ Cutaneous Malignant Melanoma.
Gonzalez A; Miles JF; Khurshid GS
Ophthalmol Retina; 2018 Jan; 2(1):71. PubMed ID: 31047306
[No Abstract] [Full Text] [Related]
2. Chemokines in the melanoma metastasis biomarkers portrait.
Neagu M; Constantin C; Longo C
J Immunoassay Immunochem; 2015; 36(6):559-66. PubMed ID: 25839711
[TBL] [Abstract][Full Text] [Related]
3. Lack of cytoplasmic ERK activation is an independent adverse prognostic factor in primary cutaneous melanoma.
Jovanovic B; Kröckel D; Linden D; Nilsson B; Egyhazi S; Hansson J
J Invest Dermatol; 2008 Nov; 128(11):2696-2704. PubMed ID: 18509361
[TBL] [Abstract][Full Text] [Related]
4. Melanoma with BRAF Mutation in Circulating Cell-free DNA despite no Mutation in the Primary Lesion: A Case Report.
Ashida A; Uhara H; Mikoshiba A; Sakaizawa K; Kumagai N; Koga H; Okuyama R
Acta Derm Venereol; 2016 Jan; 96(1):128-9. PubMed ID: 26123241
[No Abstract] [Full Text] [Related]
5. A Case of Giant Primary Dermal Melanoma with BRAF V600E Mutation.
Imamura T; Nakamura Y; Teramoto Y; Sato S; Asami Y; Arai E; Yamamoto A
Acta Derm Venereol; 2016 Aug; 96(6):840-1. PubMed ID: 26984828
[No Abstract] [Full Text] [Related]
6. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.
Kim HS; Jung M; Kang HN; Kim H; Park CW; Kim SM; Shin SJ; Kim SH; Kim SG; Kim EK; Yun MR; Zheng Z; Chung KY; Greenbowe J; Ali SM; Kim TM; Cho BC
Oncogene; 2017 Jun; 36(23):3334-3345. PubMed ID: 28092667
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous BRAF
Wuethrich A; Dey S; Koo KM; Sina AAI; Trau M
Methods Mol Biol; 2021; 2265():265-276. PubMed ID: 33704721
[TBL] [Abstract][Full Text] [Related]
8. Undifferentiated Sarcoma as Intermediate Step in Rhabdomyosarcomatous Transformation of a Metastatic Malignant Melanoma Resistant to Anti-BRAF Therapy: A Phenomenon Associated With Significant Diagnostic and Therapeutic Pitfalls.
Tran TAN
Int J Surg Pathol; 2019 Sep; 27(6):669-677. PubMed ID: 30942107
[TBL] [Abstract][Full Text] [Related]
9. Stability of BRAF V600E mutation in metastatic melanoma: new insights for therapeutic success?
Sigalotti L; Fratta E; Parisi G; Coral S; Maio M
Br J Cancer; 2011 Jul; 105(2):327-8. PubMed ID: 21694724
[No Abstract] [Full Text] [Related]
10. Clear cell melanoma: a cutaneous clear cell malignancy.
Pletneva MA; Andea A; Palanisamy N; Betz BL; Carskadon S; Wang M; Patel RM; Fullen DR; Harms PW
Arch Pathol Lab Med; 2014 Oct; 138(10):1328-36. PubMed ID: 25268196
[TBL] [Abstract][Full Text] [Related]
11. Progression of NRAS and BRAF mutations in cutaneous melanoma.
Rosso R; Romagosa Y; Kirsner RS
J Invest Dermatol; 2009 Jun; 129(6):1318. PubMed ID: 19434085
[No Abstract] [Full Text] [Related]
12. Diffuse primary malignant melanoma after prior primary cutaneous malignant melanoma.
Augsburger JJ; Shields JA; Mastrangelo MJ; Frank PE
Arch Ophthalmol; 1980 Jul; 98(7):1261-4. PubMed ID: 7396780
[TBL] [Abstract][Full Text] [Related]
13. Map3k1 Loss Cooperates with Braf
Trucco LD; Mundra PA; García-Martínez P; Hogan K; Baenke F; Dhomen N; Pavet V; Marais R
J Invest Dermatol; 2021 Jan; 141(1):221-225.e6. PubMed ID: 32450073
[No Abstract] [Full Text] [Related]
14. Primary cutaneous angiomatoid melanoma.
Fonda-Pascual P; Moreno-Arrones OM; Alegre-Sanchez A; Garcia-Del Real CM; Miguel-Gomez L; Martin-Gonzalez M
J Dtsch Dermatol Ges; 2018 Mar; 16(3):345-347. PubMed ID: 29389063
[No Abstract] [Full Text] [Related]
15. Choroidal Metastases From Cutaneous Melanoma.
Mercado CL; Toy BC; Kistler HB; Moshfeghi DM
Ophthalmic Surg Lasers Imaging Retina; 2016 May; 47(5):497. PubMed ID: 27183558
[TBL] [Abstract][Full Text] [Related]
16. A role for immunohistochemical detection of BRAF V600E prior to BRAF-inhibitor treatment of malignant melanoma?
Lade-Keller J; Kristensen LS; Riber-Hansen R; Guldberg P; Hansen LL; Steiniche T; Hager H
J Clin Pathol; 2013 Aug; 66(8):723-5. PubMed ID: 23526598
[No Abstract] [Full Text] [Related]
17. Amelanotic Malignant Melanoma with a BRAF V600E Mutation Mimicking Primary Lung Cancer.
Matsuzawa R; Morise M; Tanaka I; Hayai S; Tamiya Y; Koyama J; Hase T; Wakahara K; Kim D; Shimoyama Y; Hashimoto N
Intern Med; 2022 Mar; 61(5):703-708. PubMed ID: 34433708
[TBL] [Abstract][Full Text] [Related]
18. Identification of biomarkers to distinguish clear cell sarcoma from malignant melanoma.
Yang L; Chen Y; Cui T; Knösel T; Zhang Q; Geier C; Katenkamp D; Petersen I
Hum Pathol; 2012 Sep; 43(9):1463-70. PubMed ID: 22406360
[TBL] [Abstract][Full Text] [Related]
19. Complete Resolution of Bilateral Choroidal Metastases of Cutaneous Melanoma With Combined Targeted Therapy.
Szalai E; Csutak A; Lengyel Z
Retina; 2021 Mar; 41(3):e30-e31. PubMed ID: 33323905
[No Abstract] [Full Text] [Related]
20. Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition.
Dietrich P; Kuphal S; Spruss T; Hellerbrand C; Bosserhoff AK
Oncogene; 2018 Feb; 37(7):897-911. PubMed ID: 29059159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
